OVID Suppliers & Customers — Ovid Therapeutics Inc. Supply Chain from SEC Filings | Varamir

Sign in · build your desk

Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.

Sources

sec edgar · verbatim disclosure

Show the filing sentences· 7

Each tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.

—Northwestern Universitybuys from
“In December 2016, we entered into a license agreement ("Northwestern Agreement") with Northwestern University ("Northwestern"), pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions ("Northwestern Patent Rights") which relate to a specific compound (OV329) and related methods of use for such compound, along with certain know-how related to the practice of the inventions claimed in the Northwestern Patent Rights.”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651
—Marinus Pharmaceuticals, Inc.sells to
“Under the Marinus License Agreement, we granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consists of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorder.”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651
LGNDLigand Pharmaceuticals Incorporatedsells to
“We have otherwise primarily funded our business through the sale of our capital stock and through the entry into the royalty, license and termination agreement ("RLT Agreement") with Takeda Company Limited ("Takeda"), which resulted in a one-time up-front payment of $196.0 million in 2021 and the entry into a Royalty Monetization Agreement (the "Ligand Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand"), which resulted in a one-time up-front payment of $30.0 million in 2023.”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651
—Healx Ltdsells to
“Subsequently, we have licensed much of this portfolio to Healx Ltd, and are not further developing OV101.”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651
—AstraZenecabuys from
“We cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with AstraZeneca, Gensaic and Northwestern.”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651
TAKTakeda Company Limitedsells to
“For example, we co-developed soticlestat with Takeda Company Limited ("Takeda") through completion of Phase 2 clinical trials and subsequently sold our rights back to Takeda under a royalty, license and termination agreement ("RLT Agreement").”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651
—Gensaicbuys from
“We cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with AstraZeneca, Gensaic and Northwestern.”
FILING10-K0001628280-26-019438filed 2026-03-18cik 0001636651

Watchlist prices, news filtered to it, and its next report on your desk.